Shenzhen Weiguang Biological Products Co Ltd (SHE:002880) — Market Cap & Net Worth
Market Cap & Net Worth: Shenzhen Weiguang Biological Products Co Ltd (002880)
Shenzhen Weiguang Biological Products Co Ltd (SHE:002880) has a market capitalization of $853.26 Million (CN¥5.83 Billion) as of May 4, 2026. Listed on the SHE stock exchange, this China-based company holds position #9838 globally and #2782 in its home market, demonstrating a -2.43% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shenzhen Weiguang Biological Products Co Ltd's stock price CN¥25.71 by its total outstanding shares 226800000 (226.80 Million). Analyse cash efficiency ratio of Shenzhen Weiguang Biological Products Co to see how efficiently the company converts income to cash.
Shenzhen Weiguang Biological Products Co Ltd Market Cap History: 2017 to 2026
Shenzhen Weiguang Biological Products Co Ltd's market capitalization history from 2017 to 2026. Data shows growth from $823.21 Million to $853.26 Million (5.17% CAGR).
Shenzhen Weiguang Biological Products Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shenzhen Weiguang Biological Products Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.75x
Shenzhen Weiguang Biological Products Co Ltd's market cap is 0.75 times its annual revenue
Latest Price to Earnings (P/E) Ratio
3.54x
Shenzhen Weiguang Biological Products Co Ltd's market cap is 3.54 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $823.21 Million | $623.39 Million | $154.75 Million | 1.32x | 5.32x |
| 2018 | $612.16 Million | $687.95 Million | $156.64 Million | 0.89x | 3.91x |
| 2019 | $801.35 Million | $821.47 Million | $171.34 Million | 0.98x | 4.68x |
| 2020 | $1.11 Billion | $904.56 Million | $190.40 Million | 1.23x | 5.83x |
| 2021 | $1.05 Billion | $907.43 Million | $205.44 Million | 1.15x | 5.09x |
| 2022 | $1.04 Billion | $667.93 Million | $117.52 Million | 1.56x | 8.89x |
| 2023 | $1.16 Billion | $1.05 Billion | $218.65 Million | 1.10x | 5.29x |
| 2024 | $896.41 Million | $1.20 Billion | $253.52 Million | 0.75x | 3.54x |
Competitor Companies of 002880 by Market Capitalization
Companies near Shenzhen Weiguang Biological Products Co Ltd in the global market cap rankings as of May 4, 2026.
Key companies related to Shenzhen Weiguang Biological Products Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Shenzhen Weiguang Biological Products Co Ltd Historical Marketcap From 2017 to 2026
Between 2017 and today, Shenzhen Weiguang Biological Products Co Ltd's market cap moved from $823.21 Million to $ 853.26 Million, with a yearly change of 5.17%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥853.26 Million | +0.82% |
| 2025 | CN¥846.29 Million | -5.59% |
| 2024 | CN¥896.41 Million | -22.57% |
| 2023 | CN¥1.16 Billion | +10.79% |
| 2022 | CN¥1.04 Billion | -0.12% |
| 2021 | CN¥1.05 Billion | -5.75% |
| 2020 | CN¥1.11 Billion | +38.50% |
| 2019 | CN¥801.35 Million | +30.91% |
| 2018 | CN¥612.16 Million | -25.64% |
| 2017 | CN¥823.21 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Shenzhen Weiguang Biological Products Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $853.26 Million USD |
| MoneyControl | $853.26 Million USD |
| MarketWatch | $853.26 Million USD |
| marketcap.company | $853.26 Million USD |
| Reuters | $853.26 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Shenzhen Weiguang Biological Products Co Ltd
Shenzhen Weiguang Biological Products Co., Ltd. primarily engages in the research, development, production, and sale of blood products in China. The company offers human factor VIII, human immunoglobulin (PH4), human rabies immunoglobulin, human tetanus immunoglobulin, human hepatitis B immunoglobulin, human albumin, human histaglobulin, human firbrinogen, human immunoglobulin for intravenous inj… Read more